Toward the operational identification of adverse drug reactions.
about
Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactionsHerbal hepatotoxicity: challenges and pitfalls of causality assessment methodsA systematic review of adult admissions to ICUs related to adverse drug eventsDrug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugsPostmarketing surveillance of new drugs: II. Case studiesLymphocyte transformation studies in drug hypersensitivityA primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention.Pilot, double-blind, randomized, placebo-controlled clinical trial of the supplement food Nyaditum resae® in adults with or without latent TB infection: Safety and immunogenicityEfficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.Accidental intakes of remedies from complementary and alternative medicine in children--analysis of data from the Swiss Toxicological Information Centre.A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage.Suicide in the course of the treatment of depression.Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study GroupBridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.Postmarketing surveillance of adverse drug reactions: problems and solutionsIdentification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.A novel rapid (20-minute) IL-6 release assay using blood mononuclear cells of patients with various clinical forms of drug induced skin injuriesCausality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability.Epidemiology of adverse drug reactions in Europe: a review of recent observational studiesWhen is a clinical event an adverse drug reaction?Pharmacovigilance in children in Camagüey Province, CubaRebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicineEvaluation of the anaesthetic properties and tolerance of 1:100,000 articaine versus 1:100,000 lidocaine. A comparative study in surgery of the lower third molarAre the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?Principles of pharmacotherapy. V. Toxicology and adverse drug reactionsMethods for estimating causal relationships of adverse events with dietary supplements.An observational study of adult admissions to a medical ICU due to adverse drug events.Patterns of toxicity and factors influencing severity in acute adult trimipramine poisoning.Drug-induced Sweet's syndrome.Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study.Methods for causality assessment of adverse drug reactions: a systematic review.Herbalife hepatotoxicity: Evaluation of cases with positive reexposure testsNeglected respiratory toxicity caused by cancer therapy.Acute urticaria and angioedema: diagnostic and treatment considerations.Net efficacy adjusted for risk: further developments.
P2860
Q26743858-3A8B3527-7B93-4FC0-85AF-9F6E3AC4AE3CQ26824747-D5FDE470-E6D7-4121-B094-C381DBAA7B98Q26997090-05F64BB1-18C3-4C9D-8AAE-22D532093CC0Q27030822-ECD03D54-E882-4F4C-8F51-F6F36915535CQ28217533-10CECEBC-639D-4166-83BB-7C243D72D77DQ28324767-CF097CCF-2E3E-4AE5-94C1-C142897DF04CQ28326848-828A2B39-1CC9-48B2-A1A0-C9D58B273C45Q30564138-44645FD3-3644-4638-A9CE-957411C4DEE2Q30661684-BE514B1A-977B-43CD-8376-10E2169E4963Q31160709-1A00212D-5262-460C-B74F-D8E994499D1FQ33349202-5B49E42A-8A78-4B70-8014-309B1AD1F9DBQ33510175-EABE93FE-118D-4BD2-A369-542FAE0E8ADCQ33574076-6AC48502-821F-4345-9CC2-7AAD029ED555Q33604204-AD932F94-818A-43BD-A3DA-D8C9056EB68BQ33981058-368833FA-1A6F-4263-8770-EBB876C6E5B1Q34051886-8C9B251E-94AD-4A3C-B287-817BA12A1351Q34644792-CEAA6C99-2138-48D0-B21A-1247127BCD86Q34728381-BE4E3425-C4BE-4DEC-A8FE-9EAD3EB98EC2Q34990937-B07D22EF-424E-465F-AEE5-84FA312B051CQ35011242-668D8133-14FC-49C4-A617-81935BA94862Q35078628-855029FC-BAA4-4100-8972-9D942D2A8FB6Q35114141-1505C994-6C38-4F25-96B0-6AF19A773182Q35546999-590F5A3A-7599-4C96-B14F-EBE5AE1BB665Q35673504-22B6061E-72A4-4420-8A7F-9D88629C132DQ36028529-D7D8C483-2F25-48D4-8E06-CE28A8F30EC3Q36040552-9E9B3B7E-01DE-4BF7-B686-5FFBAD8D137EQ36055056-ADB622BC-67A9-4A1D-8C82-D0CEE9B6090EQ36251201-0AEA13E8-0528-41DD-9003-A6E5F54ECF9BQ36276552-CE9D60E3-9804-4E3B-BD12-CC6E99C93129Q36289492-C999B1EC-95F2-442B-80AC-1C298C28BC19Q36329243-4CF74396-95C8-4640-BB57-651BAEDC4332Q36526533-DC657102-50C6-4303-BB8A-18ACE01937ABQ36562507-FC706216-8E53-4E9F-AD9B-5508AA38857DQ36787636-18318510-23E5-4253-A807-04089CF85A1CQ37022433-D24A8365-FCA6-4960-AFEE-E191BFAA9F48Q37038723-8CB4BF21-C707-460E-BC1F-DC13472AF0E8Q37049109-CF809B2A-6B8B-4F60-8183-94F6CBC7AC68Q37429804-B7B52F0E-042A-49B0-A9BD-BB033C1CF09BQ37505032-4E15AD0A-59D6-46AE-8097-EB6CA0D0BD1CQ37587175-64E92F5E-26AD-4B1F-8721-656754FA34AA
P2860
Toward the operational identification of adverse drug reactions.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年学术文章
@wuu
1977年学术文章
@zh
1977年学术文章
@zh-cn
1977年学术文章
@zh-hans
1977年学术文章
@zh-my
1977年学术文章
@zh-sg
1977年學術文章
@yue
1977年學術文章
@zh-hant
name
Toward the operational identification of adverse drug reactions.
@en
Toward the operational identification of adverse drug reactions.
@nl
type
label
Toward the operational identification of adverse drug reactions.
@en
Toward the operational identification of adverse drug reactions.
@nl
prefLabel
Toward the operational identification of adverse drug reactions.
@en
Toward the operational identification of adverse drug reactions.
@nl
P356
P1476
Toward the operational identification of adverse drug reactions.
@en
P2093
P304
P356
10.1002/CPT1977213247
P407
P577
1977-03-01T00:00:00Z